| Literature DB >> 35418754 |
Yu Zhang1,2,3, Li Cui2, Yizeng Lu4, Jixiang He5, Hidayat Hussain6, Lei Xie4, Xuan Sun2, Zhaoqing Meng7, Guiyun Cao7, Dawei Qin1, Daijie Wang2,3.
Abstract
Background: The leaves of L. japonica (LLJ) are widely used as medicine in China. It is rich in caffeoylquinic acids, flavonoids and iridoid glycosides and has strong reducing capacities. Therefore, it can be used as a green material to synthesize silver nanoparticles.Entities:
Keywords: LLJ-AgNO3-NPs; antibacterial; anticancer; antioxidant; green approach; leaves of Lonicera japonica Thunb
Mesh:
Substances:
Year: 2022 PMID: 35418754 PMCID: PMC8995626 DOI: 10.2147/IJN.S356919
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1(A) UV–Vis spectra of AgNPs synthesized by LLJ at different Ag+ concentrations; (B) Silver ion conversion rate of AgNPs synthesized by LLJ at different Ag+ concentrations; (C) UV–Vis spectra of AgNPs synthesized by LLJ at different pH; (D) Silver ion conversion rate of AgNPs synthesized by LLJ at different pH; (E) UV–Vis spectra of AgNPs synthesized by LLJ at different temperatures; (F) Ag conversion rate of AgNPs synthesized by LLJ at different temperatures.
Figure 2(A) SEM image of AgNPs synthesized by LLJ; (B) TEM image of AgNPs synthesized by LLJ; (C) FTIR image of AgNPs synthesized by LLJ; (D) XRD pattern of AgNPs synthesized by LLJ; (E) XPS pattern of AgNPs synthesized by LLJ.
Figure 3Comparison of free radical DPPH clearance rate between AgNPs, LLJ, and BHT.
Figure 4Amount of viable bacteria of culture medium. (A) E. coli; (B) E. coli treated with 0.1 mg/mL LLJ; (C) E. coli treated with 0.1 mg/mL AgNPs; (D) E. coli treated with 0.1 mg/mL tetracycline; (E) Salmonella; (F) Salmonella treated with 0.1 mg/mL LLJ; (G) Salmonella treated with 0.1 mg/mL AgNPs; (H) Salmonella treated with 0.1 mg/mL tetracycline.
Figure 5The inhibition rate curves of different samples to bacteria. (A). E. coli; (B). Salmonella.
Figure 6SEM images of bacterial morphology. (A) E. coli; (B) E. coli with LLJ; (C) E. coli with AgNPs; (D) E. coli with tetracycline; (E) Salmonella; (F) Salmonella with LLJ; (G) Salmonella with AgNPs; (H) Salmonella with tetracycline.
Figure 7The inhibition rate curves of AgNPs to different cancer cell lines. (A) Hela; (B) HepG2; (C) MDA-MB-231.